Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease

Inclusion Criteria

• •Histology or cytology proven non-haematological cancer.
• •At least one lesion in the bones is required.
• •ECOG performance status ≤ 2.
• •≥ 18 years old.
• •Life expectancy \> 6 months.
• •GTV diameter ≤ 5 cm.
• •In case of de novo OMD and OMD recurrence a maximum of 5 targets (including the primary tumour) in a maximum of 3 organ sites are allowed.
• •In case of OPD \* and induced OMD\*2 only 3 metastases (including the primary tumour) are allowed.
• •The metastatic lesion(s) must be visible on a CT- or MR- scan and suitable for treatment with SABR.
• •All metastatic sites are treated or planned for ablative therapy (including surgery) - for OPD only the sites in progression is required to fulfil this criterion. • A baseline scan within 28 days of inclusion (CT or PET- CT).
• •For spine/paraspinal targets, an MR scan is mandatory, if epidural growth cannot be precluded on the baseline CT scan.
• •No curative intended treatment option available.
• •An ablative strategy should be deemed clinically relevant and is at the discretion of the treating physician to decide.
• •Ability to understand and the willingness to sign a written informed consent document.